Uric Acid and Treatment With Empagliflozin in Heart Failure with Preserved Ejection Fraction (HFpEF): the EMPEROR-Preserved Trial

被引：0
|
作者：
Green, Jennifer [1 ,2 ]
机构：
[1] Duke Univ, Dept Med, Duke Clin Res Inst, Med Ctr, Durham, NC USA
[2] Duke Univ, Med Ctr, Div Endocrinol, Durham, NC USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2023年 / 142卷
关键词：
empagliflozin; heart failure; HFpEF; hyperuricemia; SGLT2;
D O I：
10.1016/j.metabol.2023.155468
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0074
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [41] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of blood pressure: the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Saloustros, I.
    Schueler, E.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 132 - 132
  • [42] Design and rationale of the EMPagliflozin outcomE tRial in patients with chrOnic heaRt failure (EMPEROR-Preserved)
    Butler, J.
    Packer, M.
    Filippatos, G.
    Zannad, F.
    Salsali, A.
    Kimura, K.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J.
    Brueckmann, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 232 - 232
  • [43] Empagliflozin improves cardiovascular and renal outcomes in patients with preserved ejection fraction irrespective of age: insights from the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, J.
    Filippatos, G.
    Ferreira, J. P.
    Pocock, S. J.
    Abdin, A.
    Mahfoud, F.
    Brueckmann, M.
    Gollop, N. D.
    Iwata, T.
    Ponikowski, P.
    Wanner, C.
    Zannad, F.
    Packer, M.
    Anker, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 131 - 132
  • [44] Heart failure outcomes according to heart rate and effects of empagliflozin in patients of the EMPEROR-Preserved trial
    Boehm, Michael
    Butler, Javed
    Mahfoud, Felix
    Filippatos, Gerasimos
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Slawik, Jonathan
    Brueckmann, Martina
    Linetzky, Bruno
    Schueler, Elke
    Wanner, Christoph
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) : 1883 - 1891
  • [45] heart failure with preserved ejection fraction(HFpEF) in elderly
    Sinha, A. K.
    Sinha, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 92 - 92
  • [46] PREDICTORS OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFPEF)
    Kumar, A.
    Saluja, A. K.
    Khan, A.
    Gandhi, D.
    Morsy, M. A.
    Khalife, W. I.
    CARDIOLOGY, 2014, 128 : 467 - 468
  • [47] Heart peptides and HFpEF (heart failure with preserved ejection fraction)
    Takahashi, Kazuhiro
    PEPTIDES, 2022, 157
  • [48] The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction
    Volpe, Massimo
    Patrono, Carlo
    EUROPEAN HEART JOURNAL, 2021, 42 (45) : 4621 - 4623
  • [49] Heart Failure and a Preserved Ejection Fraction A Side-by-Side Examination of the PARAGON-HF and EMPEROR-Preserved Trials
    Packer, Milton
    Zannad, Faiez
    Anker, Stefan D.
    CIRCULATION, 2021, 144 (15) : 1193 - 1195
  • [50] Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
    Takeuchi, Shinsuke
    Kohno, Takashi
    Goda, Ayumi
    Shiraishi, Yasuyuki
    Saji, Mike
    Nagatomo, Yuji
    Tanaka, Toshikazu D.
    Takei, Makoto
    Nakano, Shintaro
    Soejima, Kyoko
    Kohsaka, Shun
    Yoshikawa, Tsutomu
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 370 : 263 - 270
12345